ArticleRespiratory research2020
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis.
Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 91 citations in OpenAlex.
- Isolated nonparathyroid hormone-mediated hypercalcemia: a rare presentation of retroperitoneal sarcoidosis.JCEM case reports · 2026Article
- Biomarkers and genetic determinants of cardiac sarcoidosis: current status, the unmet needs and future perspectives.Frontiers in cardiovascular medicine · 2026Review
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
- New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.Frontiers in immunology · 2026Article
- Pilot study identifying distinct circulating proteomic profiles associated with longitudinal CT-defined fibrotic and inflammatory sarcoidosis.Frontiers in immunology · 2026Article
- Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.Seminars in respiratory and critical care medicine · 2025Review
- New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.bioRxiv : the preprint server for biology · 2025Article
- Myopathology and Immune Profile of Granulomatous Myositis in Sarcoid Myopathy.Neuropathology and applied neurobiology · 2025Article
- An Important Question: Can Serum Chitotriosidase Enzyme Predict the Activity and Clinical Course of Sarcoidosis Disease?Thoracic research and practice · 2025Article
- Article
- IgG4-related disease and other fibro-inflammatory conditions.Nature reviews. Rheumatology · 2025Review
- A structured list of laboratory tests for screening the possible causes of small fiber neuropathy in clinical practice.Frontiers in neurology · 2025Review
- Transcriptomic profiling of granuloma in patients with cardiac sarcoidosis.Theranostics · 2025Article
- Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions.Cureus · 2024Review
- Sarcoidosis versus Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency: A Comparative Review.Biomedicines · 2024Review
- Article
- Diagnostic Value of Imaging and Serological Biomarkers in Pulmonary Sarcoidosis.Advances in respiratory medicine · 2024Review
- Phenotypes and Serum Biomarkers in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2024Review
- High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities.Diagnostics (Basel, Switzerland) · 2024Review
- Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum chitotriosidase is a promising biomarker that has shown high specificity and sensitivity in patients with sarcoidosis. The aim of this study was to investigate correlations between serum chitotriosidase, clinical phenotypes, disease localizations and different radiological lung involvement and to identify clinical features associated with over-expression of chitotriosidase in a large cohort of sarcoidosis patients.
methodsChitotriosidase activity was evaluated in a population of 694 consecutive patients (males 39%, age 55.8 ± 12.8 years). Clinical and respiratory functional characteristics, Clinical Outcome Scale (COS) classification, clinical phenotypes proposed by the GenPhenResA project, and radiological assessment, including CT scan, were collected. Serum sampling and clinical and functional assessments at follow-up were also included.
resultsSignificantly higher chitotriosidase activity was observed in sarcoidosis patients than in healthy controls (p < 0.0001). Evidence of lung fibrosis with reticular abnormalities and traction bronchiectasis at High resolution CT, presence of multiple extrapulmonary sarcoid localizations and increased 24-h urinary excretion of calcium were associated with significantly higher chitotriosidase activity (p < 0.005). Patients with remitted or minimal disease had lower values of chitotriosidase than patients with persistent disease. At follow-up, patients who required an increase in steroid dose showed an increase in its activity.
conclusionsChitotriosidase is a reliable biomarker of sarcoidosis. It is increased in patients with sarcoidosis correlating with disease activity, severity and multiorgan dissemination. Steroid therapy tended to reduce chitotriosidase expression, however it responded in cases of disease relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.